Vivoryon Therapeutics N.v. · EURONEXT:VVY
Vivoryon Therapeutics — Investor Presentation (November 2024)
17 slides from Vivoryon Therapeutics's investor presentation, November 2024
Slide 1: Improving Kidney Health Outcomes
Improving Kidney Health Outcomes Lead Program: Varoglutamstat in Diabetic Kidney Disease November 2024 Vivoryon Therapeutics N.V.
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This document has been prepared by Vivoryon Therapeutics N.V. (the “Company” or “We”) strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment
Slide 3: Compelling investment case: Vivoryon's varoglutamstat improves kidney health
Compelling investment case: Vivoryon’s varoglutamstat improves kidney health Groundbreaking Inhibition of QPCTL reduces kidney inflammation and fibrosis discovery Breakthrough Varoglutamstat – first in class QPCT/L inhibitor – shows a large and statistically clinical results significant improvement
Slide 4: Groundbreaking discovery: Inhibition of QPCTL reduces kidney inflammation and fibrosis
Groundbreaking discovery: Inhibition of QPCTL reduces kidney inflammation and fibrosis, and improves kidney function Varoglutamstat substrate protein pyroglutamate inflammatory Pro-inflammatory chemokines QPCTL and fibrotic inhibition leads peptides require to reduction in pyroglutamate QPCTL pE-CCL
Slide 5: Robust research supports development of QPCTL inhibitors in kidney and liver disorders
Robust research supports development of QPCTL inhibitors in inflammatory and fibrotic kidney and liver disorders Pharmacological inhibition of the chemokine Inflammation/kidney disease CCL2 (MCP-1) diminishes liver macrophage publications past 40 years* infiltration and steatohepatitis in chronic he
Slide 6: Breakthrough clinical results: Statistically significant improvement in eGFR over two years
Breakthrough clinical results: Statistically significant improvement in prospectively defined eGFR over two years in Phase 2 study Validated regulatory primary endpoint All subjects Diabetes Change in eGFR over time Change in eGFR over time Slope analysis Slope analysis Protocol for VIVIAD Phase 2b
Slide 7: Consistency of results using diverse and validated methods for eGFR assessment
Consistency of results using diverse and validated methods for eGFR assessment Sensitivity analysis: baseline adjusted treatment effect of varoglutamstat versus placebo Method used 2021 CKD-EPI cystatin C 2021 CKD-EPI creatinine * **** 10 9.49 ** *** 10 9 9 varoglutamstat vs. placebo eGFR treatment
Slide 8: Clear dose-finding results strongly correlated with MoA and biomarker
Clear dose-finding results strongly correlated with MoA and biomarker Reduction of pE-CCL2 correlates with improvement of eGFR Varoglutamstat effect on kidney function outcomes Median reduction in pE-CCL2 levels at week 48 (total population; change in eGFR over time (MDRD)1) compared to baseline wit
Slide 9: Excellent safety profile consistent across two years of study duration
Excellent safety profile consistent across two years of study duration Extensive safety package VIVIAD Phase 2b study (# / duration) % of patients with at least one TEAE1 Pharmacology / Phase 1 ◆ Phase 1 study: large trial with 205 subjects ◆ Human ADME / mass balance study completed Phase 2 double-
Slide 10: Outstanding commercial potential: available medicines only slow disease progression in DKD
Outstanding commercial potential: Currently available, highly successful medicines only slow disease progression in DKD SGLTi eGFR (compiled)4 SGLT2 GLP-1 QPCT/L Drug / Trial name Canagliflozin Dapagliflozin Semaglutide Varoglutamstat CREDENCE1 DAPA-CKD2 FLOW3 VIVIAD Diabetes subgroup Annualized eGF
Slide 11: DKD is the leading cause of end stage kidney disease
DKD1 is the leading cause of end stage kidney disease (ESKD) Inflammation and fibrosis are key underlying pathways in DKD Diabetes is a leading cause of Diabetes is a significant and end-stage kidney disease2 growing global challenge (adults aged 20-79 years with diabetes, worldwide) 3 783M 2045 643
Slide 12: Planned Phase 2 study in stage 3b/4 DKD on top of standard of care
Planned Phase 2 study in stage 3b/4 DKD on top of standard of care 1 Draft study design, with anticipated interim analysis at 15 months after study start Enrollment: Persistent albuminuria categories Description and range ◆ Patients: Diabetes patients with CKD 3b/4 eGFR Normal to Moderately Severely
Slide 13: Vivoryon: A history of groundbreaking discoveries and developments
Vivoryon: A history of groundbreaking discoveries and developments Seminal R&D in diabetes & development of new class SAPHIR Phase 2a VIVIAD Phase 2 of oral antidiabetic agents, the study data with results reveal DPP-4 inhibitors (gliptins) varoglutamstat in AD Introduced exciting kidney Started dev
Slide 14: A trusted company: Senior management team with a strong track record
A trusted company: Senior management team with a strong track record Executive Directors Frank Weber, MD Anne Doering, CFA Michael Schaeffer, PhD Chief Executive Officer Chief Financial Officer Chief Business Officer Non-executive Directors Erich Platzer, MD, PhD Charlotte Lohmann Claudia Riedl, PhD
Slide 15: Looking ahead: Upcoming value drivers
Looking ahead: Upcoming value drivers 2026+ 2025 Ph. 2 interim data (~15 months post P2 initiation) 2024 Orphan kidney pre- clinical data Ph. 2 full data VIVIAD kidney data ✓ (~15 months post P2 interim) at ASN Oct. 2024 Start Ph. 2 DKD study1 VIVA-MIND data EOY 2024 Potential to start small orphan
Slide 16: Vivoryon: Mid-stage clinical biotech company with first-in-class QPCT/L inhibitor
Vivoryon: Mid-stage clinical biotech company with first-in-class QPCT/L inhibitor varoglutamstat targeting high unmet need in kidney disease Strong scientific base with novel MoA Compelling long-term efficacy showing improvement in kidney function Extensive safety data package for varoglutamstat Foc
Slide 17: Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany Info@vivoryon.com +49 (0)345 555 99 00 www.vivoryon.com
Vivoryon Therapeutics — Investor Presentation (November 2024) on 6ix